Skip to search formSkip to main contentSkip to account menu

LY2090314

Known as: 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione, LY 2090314, GSK-3 Inhibitor LY2090314 
An inhibitor of glycogen synthase kinase-3 (GSK-3), with potential antineoplastic activity. Upon administration, LY2090314 binds to and inhibits GSK… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BackgroundNeuroblastoma (NB) is a devastating disease. Despite recent advances in the treatment of NB, about 60% of high-risk NB… 
2016
2016
Abstract This open-label, Phase-2 study investigated the safety of LY2090314 (GSK-3 inhibitor) in AML patients. Twenty patients… 
Highly Cited
2016
Highly Cited
2016
A substrate peptide that the kinase GSK-3 converts into its own inhibitor improves symptoms and cognitive function in an… 
Highly Cited
2015
Highly Cited
2015
It has previously been observed that a loss of β-catenin expression occurs with melanoma progression and that nuclear β-catenin… 
2015
2015
SummaryPurpose LY2090314 (LY) is a glycogen synthase kinase 3 inhibitor with preclinical efficacy in xenograft models when… 
2013
2013
LY2090314 (3-[9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indol-7-yl]-4-imidazo[1,2-a]pyridin-3… 
Highly Cited
2011
Highly Cited
2011
Glycogen synthase kinase-3 (GSK-3) unique position in modulating the function of a diverse series of proteins in combination with… 
Highly Cited
2000
Highly Cited
2000
Eukaryotic initiation factor eIF-2B plays an important role in translation regulation and has been suggested to be implicated in…